First Eagle Investment Management, LLC Pacira Bio Sciences, Inc. Transaction History

First Eagle Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$26.32 - $34.31 $2.75 Million - $3.59 Million	-104,551 Reduced 50.35%	103,081 $3.48 Million
Q3 2023 Nov 08, 2023	SELL	$30.68 - $40.09 $1.12 Million - $1.47 Million	-36,640 Reduced 15.0%	207,632 $6.37 Million
Q2 2023 Aug 09, 2023	BUY	$36.12 - $47.5 $2.45 Million - $3.22 Million	67,847 Added 38.46%	244,272 $9.79 Million
Q1 2023 May 11, 2023	BUY	$35.53 - $43.38 $3.32 Million - $4.05 Million	93,412 Added 112.53%	176,425 $7.2 Million
Q4 2022 Feb 09, 2023	BUY	$38.19 - $57.45 $171,167 - $257,490	4,482 Added 5.71%	83,013 $3.21 Million
Q3 2022 Nov 10, 2022	BUY	$51.24 - $58.89 $446,095 - $512,696	8,706 Added 12.47%	78,531 $4.18 Million
Q2 2022 Aug 10, 2022	BUY	$51.49 - $81.64 $1.14 Million - $1.8 Million	22,104 Added 46.32%	69,825 $4.07 Million
Q1 2022 May 11, 2022	BUY	$60.03 - $76.49 $1.37 Million - $1.75 Million	22,889 Added 92.18%	47,721 $3.64 Million
Q4 2021 Feb 10, 2022	BUY	$47.97 - $62.21 $1.19 Million - $1.54 Million	24,832 New	24,832 $1.49 Million

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of First Eagle Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Eagle Investment Management, LLC with notifications on news.